OBJECTIVE: The purpose of this study was to evaluate enhancement characteristics of hepatocellular adenomas (HCAs) using gadoxetic acid as a hepatocyte-specific MR contrast agent. METHODS: Twenty-four patients with histopathologically proven HCAs were retrospectively identified. MRI consisted of T1- and T2-weighted (w) sequences with and without fat saturation (fs), multiphase dynamic T1-w images, and fs T1-w images during the hepatobiliary phase. Standard of reference was surgical resection (n = 19) or biopsy (n = 5). Images were analysed for morphology and contrast behaviour including signal intensity (SI) measurement on T1-w images normalised to the pre-contrast base line. RESULTS: In total 34 HCAs were evaluated. All HCAs showed enhancement in the arterial phase; 38 % of HCAs showed reduced contrast enhancement ("wash-out") in the venous phase. All HCAs showed enhancement (SI increase, 56 ± 53 %; P <0.001) in the hepatobiliary phase, although liver uptake was stronger (96 ± 58 %). Thus, 31 of all HCAs (91 %) appeared hypointense to the surrounding liver in the hepatobiliary phase, while 3 out of 34 lesions were iso-/hyperintense. CONCLUSIONS: Gadoxetic acid accumulates in HCAs in the hepatobiliary phase, although significantly less than in surrounding liver. Thus, HCA appears in the vast majority of cases as a hypointense lesion on hepatobiliary phase images. KEY POINTS: • Magnetic resonance-specific contrast agents are now available for hepatic imaging. • Hepatocellular adenomas enhance with gadoxetic acid as in previous CT/MRI experience. • Enhancement during the hepatobiliary phase is less in HCAs than in liver. • Typical HCAs appear as hypointense lesions on T1-w hepatobiliary phase images. • True hyperintense HCA enhancement can occasionally occur during the hepatobiliary phase.
OBJECTIVE: The purpose of this study was to evaluate enhancement characteristics of hepatocellular adenomas (HCAs) using gadoxetic acid as a hepatocyte-specific MR contrast agent. METHODS: Twenty-four patients with histopathologically proven HCAs were retrospectively identified. MRI consisted of T1- and T2-weighted (w) sequences with and without fat saturation (fs), multiphase dynamic T1-w images, and fs T1-w images during the hepatobiliary phase. Standard of reference was surgical resection (n = 19) or biopsy (n = 5). Images were analysed for morphology and contrast behaviour including signal intensity (SI) measurement on T1-w images normalised to the pre-contrast base line. RESULTS: In total 34 HCAs were evaluated. All HCAs showed enhancement in the arterial phase; 38 % of HCAs showed reduced contrast enhancement ("wash-out") in the venous phase. All HCAs showed enhancement (SI increase, 56 ± 53 %; P <0.001) in the hepatobiliary phase, although liver uptake was stronger (96 ± 58 %). Thus, 31 of all HCAs (91 %) appeared hypointense to the surrounding liver in the hepatobiliary phase, while 3 out of 34 lesions were iso-/hyperintense. CONCLUSIONS:Gadoxetic acid accumulates in HCAs in the hepatobiliary phase, although significantly less than in surrounding liver. Thus, HCA appears in the vast majority of cases as a hypointense lesion on hepatobiliary phase images. KEY POINTS: • Magnetic resonance-specific contrast agents are now available for hepatic imaging. • Hepatocellular adenomas enhance with gadoxetic acid as in previous CT/MRI experience. • Enhancement during the hepatobiliary phase is less in HCAs than in liver. • Typical HCAs appear as hypointense lesions on T1-w hepatobiliary phase images. • True hyperintense HCA enhancement can occasionally occur during the hepatobiliary phase.
Authors: D J van der Windt; N F M Kok; S M Hussain; P E Zondervan; I P J Alwayn; R A de Man; J N M IJzermans Journal: Br J Surg Date: 2006-12 Impact factor: 6.939
Authors: L Arrivé; J F Fléjou; V Vilgrain; J Belghiti; D Najmark; M Zins; Y Menu; J M Tubiana; H Nahum Journal: Radiology Date: 1994-11 Impact factor: 11.105
Authors: Julian A Luetkens; Patrick A Kupczyk; Jonas Doerner; Rolf Fimmers; Winfried A Willinek; Hans H Schild; Guido M Kukuk Journal: Eur Radiol Date: 2015-04-23 Impact factor: 5.315
Authors: E Reizine; M Ronot; M Ghosn; J Calderaro; N Frulio; P Bioulac-Sage; H Trillaud; V Vilgrain; V Paradis; A Luciani Journal: Eur Radiol Date: 2020-11-04 Impact factor: 5.315
Authors: So Jung Lee; So Yeon Kim; Kyoung Won Kim; Yong Moon Shin; Hyoung Jung Kim; Jong Seok Lee; Sun A Kim Journal: Clin Mol Hepatol Date: 2012-09-25
Authors: Charles Balabaud; Wesal R Al-Rabih; Pei-Jer Chen; Kimberley Evason; Linda Ferrell; Juan C Hernandez-Prera; Shiu-Feng Huang; Thomas Longerich; Young Nyun Park; Alberto Quaglia; Peter Schirmacher; Christine Sempoux; Swan N Thung; Michael Torbenson; Aileen Wee; Matthew M Yeh; Shiou-Hwei Yeh; Brigitte Le Bail; Jessica Zucman-Rossi; Paulette Bioulac-Sage Journal: Int J Hepatol Date: 2013-04-14